Sol-Gel Technologies Ltd.
SLGLNasdaq
$83.20
↑ +6.6%Jul 17 close · end-of-day
Price
1Y↑ +896.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$231.8M
Enterprise Value
$207.5M
P/E
—
P/S
12.0
P/B
7.3
EV/EBITDA
—
PEG
—
FCF Yield
0.1%
Dividend Yield
—
Revenue (TTM)
$19.4M
Net Income (TTM)
-$6.1M
Free Cash Flow (TTM)
$275,000.00
Gross Margin
—
Operating Margin
-38.9%
Net Margin
-31.6%
ROE
-19.2%
ROIC
-78.3%
Debt / Equity
—
Net Cash
$24.3M
Return 1Y
+889.7%
Company profile
Sol-Gel Technologies Ltd. focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris, Epsolay, SGT-210, and Erlotinib, Tapinarof, and roflumilast are the company's lead product candidates.
- CEO
- Alon Seri-Levy
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Website
- sol-gel.com
Earnings
SLGL Q2 2025 Earnings
Period ends 2025-06-30
MetricActualYoY
Revenue$17.3M↑ +217.7%
Diluted EPS$4.17↑ +487.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $31.3M | $3.9M | $1.6M | $11.5M | $19.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$30.2M | $3.0M | -$16.2M | -$29.3M | -$12.0M | -$7.5M |
| Net income | -$29.3M | $3.2M | -$14.9M | -$27.2M | -$10.6M | -$6.1M |
| Diluted EPS | -$1.30 | $0.14 | -$0.65 | -$10.01 | -$3.79 | -$2.19 |
| Operating cash flow | -$25.2M | -$7.7M | -$9.5M | -$17.7M | -$13.9M | $322,000.00 |
| Free cash flow | -$25.7M | -$7.8M | -$9.7M | -$17.9M | -$13.9M | $275,000.00 |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -344.7% | 9.5% | -418.3% | -1885.8% | -104.1% | -38.9% |
| Net margin | -333.9% | 10.3% | -384.3% | -1752.8% | -91.7% | -31.6% |
| Line item | Q2 '21 | Q2 '22 | Q2 '23 | Q2 '24 | Q2 '25 |
|---|---|---|---|---|---|
| Revenue | $928,000.00 | $3.5M | $594,000.00 | $5.4M | $17.3M |
| Gross profit | — | — | — | — | — |
| Operating income | -$8.0M | -$463,000.00 | -$6.5M | $1.6M | $11.2M |
| Net income | -$8.0M | -$134,000.00 | -$6.0M | $2.0M | $11.6M |
| Diluted EPS | $0.35 | $0.01 | -$0.22 | $0.71 | $4.17 |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | -866.6% | -13.2% | -1098.8% | 29.9% | 65.1% |
| Net margin | -865.6% | -3.8% | -1005.1% | 36.4% | 67.3% |
Company news
May 28, 2026
Mar 24, 2026
Mar 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.